JCO:这种癌也被过度诊断了?CSCO专家呼吁为其改名!

2022-04-26 MedSci原创 MedSci原创

专家认为取消GS6的癌症标签将极大地改善个人和公共健康。而这类患者需要做的只是采取积极监测,而无需立即采取治疗。

前列腺特异性抗原(PSA)是检测前列腺癌的重要指标,然而PSA筛查对前列腺癌(PCa)仍有很大争议,主要是因为不清楚降低转移率和癌症死亡率的主要好处是否值得过度诊断、过度治疗和潜在的治疗相关疾病的风险。

导致过度诊断和过度治疗的一个主要因素是将前列腺中特定的低级细胞变化模式定为癌症。近期,来自CSCO的专家在《临床肿瘤学杂志》(Journal of Clinical Oncology)发文指出,低级别前列腺癌不应该再被称为癌症。对这些病变进行简单的术语修改,并去掉癌症的标签,将大大减少过度诊断和过度治疗,并明显改变PSA筛查的成本-效益计算。

过度诊断流行病的根源在于50岁以上的男性中>30%(到80岁时>60%)会出现组织学PCa,因为如果一个人活得足够长,几乎所有的前列腺都会最终发展出微小的PCa。病理学结果GS6(即Gleason评分为6,为低级别)是一种自然的、与年龄有关的组织学观察,被人为地定义为一种疾病,不知道会引起症状或转移,但矛盾的是导致侵入性监测或治疗。这些担忧是导致美国预防服务工作组在2012年明确不鼓励PCa筛查的一个主要因素,特别指出了对 "微小的、分化良好的病变......不太可能有临床意义 "的常见诊断和治疗。

虽然GS6符合癌症的病理标准(侵入基质),但如果没有同时存在更高等级的疾病(GS≥7;即等级组≥2),它实际上不可能侵入邻近的局部结构或发生转移。当手术切除前列腺并术后证实为GS6时,尽管癌症通常已存在多年,甚至几十年,基本上100%不会发生转移。当癌症相关的死亡率接近0%,甚至在没有治疗的情况下也是如此,是时候应考虑修改筛查、诊断、管理和术语模式。

此外,无论医生花多少时间来淡化GS6诊断的重要性或强调低风险,"你得了癌症 "这句话对大多数男性和他们的家人都有强大的心理影响。

GS6患者15年内转移/死亡率低于1%

尽管与癌症相关的风险可以忽略不计,但PCa的诊断与抑郁症和自杀的风险增加有关,即使是低级别的PCa。同时,过度治疗往往会带来性功能障碍或尿失禁等副作用。而既往研究结果显示,低级别前列腺癌患者15年内转移/死亡率甚至低于1%。

因此,专家认为取消GS6的癌症标签将极大地改善个人和公共健康。而这类患者需要做的只是采取积极监测,而无需立即采取治疗。

参考文献:

Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. https://ascopubs.org/doi/full/10.1200/JCO.22.00123

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891693, encodeId=660b1891693c8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 11 17:04:36 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234021, encodeId=cb65123402135, content=同感, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Fri Jul 22 14:29:52 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081171, encodeId=742720811e11a, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Dec 15 21:04:36 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214663, encodeId=2f72121466376, content=甲状腺癌是否也存在类似情况?, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Tue Apr 26 17:21:03 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214636, encodeId=60df12146362e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Apr 26 15:50:27 CST 2022, time=2022-04-26, status=1, ipAttribution=)]
    2022-12-11 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891693, encodeId=660b1891693c8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 11 17:04:36 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234021, encodeId=cb65123402135, content=同感, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Fri Jul 22 14:29:52 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081171, encodeId=742720811e11a, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Dec 15 21:04:36 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214663, encodeId=2f72121466376, content=甲状腺癌是否也存在类似情况?, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Tue Apr 26 17:21:03 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214636, encodeId=60df12146362e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Apr 26 15:50:27 CST 2022, time=2022-04-26, status=1, ipAttribution=)]
    2022-07-22 走,走走

    同感

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1891693, encodeId=660b1891693c8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 11 17:04:36 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234021, encodeId=cb65123402135, content=同感, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Fri Jul 22 14:29:52 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081171, encodeId=742720811e11a, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Dec 15 21:04:36 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214663, encodeId=2f72121466376, content=甲状腺癌是否也存在类似情况?, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Tue Apr 26 17:21:03 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214636, encodeId=60df12146362e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Apr 26 15:50:27 CST 2022, time=2022-04-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1891693, encodeId=660b1891693c8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 11 17:04:36 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234021, encodeId=cb65123402135, content=同感, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Fri Jul 22 14:29:52 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081171, encodeId=742720811e11a, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Dec 15 21:04:36 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214663, encodeId=2f72121466376, content=甲状腺癌是否也存在类似情况?, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Tue Apr 26 17:21:03 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214636, encodeId=60df12146362e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Apr 26 15:50:27 CST 2022, time=2022-04-26, status=1, ipAttribution=)]
    2022-04-26 weigq

    甲状腺癌是否也存在类似情况?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1891693, encodeId=660b1891693c8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 11 17:04:36 CST 2022, time=2022-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234021, encodeId=cb65123402135, content=同感, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Fri Jul 22 14:29:52 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081171, encodeId=742720811e11a, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Dec 15 21:04:36 CST 2022, time=2022-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214663, encodeId=2f72121466376, content=甲状腺癌是否也存在类似情况?, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Tue Apr 26 17:21:03 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214636, encodeId=60df12146362e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c526402168, createdName=ms5000000686165165, createdTime=Tue Apr 26 15:50:27 CST 2022, time=2022-04-26, status=1, ipAttribution=)]
    2022-04-26 ms5000000686165165

    学习

    0

相关资讯

Radiology:多参数MRI在诊断前列腺导管腺癌中的价值

前列腺导管腺癌(DAC)是前列腺癌的第二大组织学亚型,大多数DAC是与PAC混合发生的肿瘤。

Radiology:对DWI的深度学习重建提高了前列腺成像的图像质量

深度学习重建(DLR)技术已被引入临床以改善MRI扫描质量,对改善图像质量和诊断性能的效用已经在MR冠状动脉造影和膝关节、盆腔和脑部成像中得到证实

Br J Cancer:5-氨基酮戊酸增加线粒体活性氧的产生降低前列腺癌的放疗抗性

5-ALA联合放射性疗法的治疗策略能够提高放疗对前列腺癌的治疗效果

英国MHRA已针对镥 (177Lu) vipivotide tetraxetan早期治疗前列腺癌发表了积极意见

镥 (177Lu) vipivotide tetraxetan 联合 SOC 组的中位 OS 为 15.3 个月,而 SOC 单独组为 11.3 个月。

Lancet Oncol:大剂量放疗+长期雄激素剥夺治疗前列腺癌的10年随访结果

大剂量放疗+长期雄激素剥夺治疗可改善高危型前列腺癌患者预后

拓展阅读

Eur Urol Focus:转移性前列腺癌患者液体活检样本和肿瘤组织的二代测序可行性如何?

研究人员在前列腺癌患者中,分析了液体活检和肿瘤组织样本进行二代测序(NGS)的可行性和可比性。结果发现,液体活检 NGS 的 BRCA1/2 基因变异检出率更高。

Eur Urol:前列腺癌磁共振成像可见病灶靶向活检的过高分级是否会导致过度治疗?

研究人员评估了磁共振靶向活检是否会导致过度治疗。结果发现,靶向活检结果会导致高风险的过度治疗。

Eur Urol:寡复发转移性前列腺癌的系统和肿瘤导向疗法

研究人员发现,在强效全身治疗的基础上加用转移灶定向 SBRT 治疗可以在睾酮恢复后维持较低的 PSA。

赵建夫教授揭秘前列腺癌治疗前沿与未来展望

「医悦汇」邀请到暨南大学附属第一医院赵建夫教授,来分享前列腺癌治疗领域的最新临床治疗进展和在抗击前列腺癌这一顽疾上所取得的成就及面临的挑战。

Eur Urol Focus:经会阴或经直肠磁共振成像靶向活检在前列腺癌检测中的比较

研究人员比较 TRBx 和 TPBx 的 csPCa 检出率情况。结果发现,TPBx 的 csPCa 检出率更高。

Eur Urol Oncol:三个月和七个月前列腺特异性抗原水平能否作为转移性激素敏感性前列腺癌总生存期的预后指标?

研究人员评估了前列腺特异性抗原水平与转移性激素敏感性前列腺癌患者总生存期(OS)的关系。结果发现,PSA-3个月和PSA-7个月反应与 OS 密切相关。